36 filings
8-K
PRDS
Pardes Biosciences Inc
31 Aug 23
Pardes Biosciences Announces Closing of Tender Offer
8:59am
8-K
PRDS
Pardes Biosciences Inc
17 Jul 23
Entry into a Material Definitive Agreement
7:06am
8-K
PRDS
Pardes Biosciences Inc
5 Jun 23
Departure of Directors or Certain Officers
4:02pm
8-K
PRDS
Pardes Biosciences Inc
18 May 23
Departure of Directors or Certain Officers
4:10pm
8-K
PRDS
Pardes Biosciences Inc
5 May 23
Pardes Biosciences Reports First Quarter 2023 Financial Results
4:02pm
8-K
778gk
21 Apr 23
Departure of Directors or Certain Officers
4:15pm
8-K
qb9mzv6qpdym9y ua8z
3 Apr 23
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
8:00am
8-K
gkln6 e5zp
14 Mar 23
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:04pm
8-K
53gl88ta
7 Nov 22
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
4:00pm
8-K
v9ht1v0f es
17 Oct 22
Departure of Directors or Certain Officers
4:14pm
8-K
760 p7h4s0ekyux0dr
14 Sep 22
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
8:02am
8-K
kihrab riewpjb5i9
13 Sep 22
Other Events
8:02am
8-K
kgc8rn vw6
15 Aug 22
Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
8:06am
8-K
8kbaryysissw5uq
10 Jun 22
Submission of Matters to a Vote of Security Holders
4:02pm
8-K
frlovbklm3j m6vl7q
9 Jun 22
Other Events
6:04am
8-K
jsnjoau
10 May 22
Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
8-K
gk6pq
29 Mar 22
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
4:05pm
8-K
bf572g yd
24 Mar 22
Regulation FD Disclosure
4:03pm
8-K
blrfd7yk
9 Mar 22
Regulation FD Disclosure
11:12am
8-K
d8l4bxtp2zw1j o01
2 Mar 22
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
4:16pm